Use of hormone therapies in disseminated carcinomatosis of the bone marrow associated with hormone receptor-positive breast cancer

被引：3
|
作者：
Ota, Takayo [1 ]
Miyatake, Nozomi [1 ]
Tanaka, Noriko [2 ]
Hasegawa, Yoshikazu [1 ]
Tokunaga, Masahiro [2 ]
Tsukuda, Hiroshi [1 ]
Fukuoka, Masahiro [1 ]
机构：
[1] Izumi Municipal Hosp, Dept Med Oncol, 4-10-10 Fuchu, Izumi, Osaka 5940071, Japan
[2] Izumi Municipal Hosp, Dept Radiol, Izumi, Osaka, Japan
来源：
GYNECOLOGICAL ENDOCRINOLOGY | 2018年 / 34卷 / 04期
关键词：
Breast cancer; disseminated carcinomatosis of the bone marrow; hormone therapy; zoledronic acid; GASTRIC-CANCER; METASTASIS; PROGNOSIS;
D O I：
10.1080/09513590.2017.1393063
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Disseminated carcinomatosis of the bone marrow (DCBM) is diffusely invasive bone metastasis resulting from solid tumors. DCBM is often associated with disseminated intravascular coagulation (DIC) or hemolytic anemia. Generally, DCBM treatment includes cytotoxic chemotherapy for underlying solid tumors and management of hematological conditions if present. We report a case of DCBM accompanied with DIC in hormone receptor-positive breast cancer. Due to her life-threatening condition, we used hormone therapies, not cytotoxic chemotherapies, to treat her DCBM. With zoledronic acid, her DIC and general condition gradually improved and eventually she could return to her daily life. If DCBM occurs in hormone receptor-positive breast cancer, hormone therapy can be one of the treatment choices.
引用
收藏
页码：286 / 289
页数：4
相关论文
共 50 条
  • [1] Use of hormone therapies in disseminated carcinomatosis of the bone marrow associated with hormone receptor-positive breast cancer (vol 34, pg 286, 2018)
    Ota, T.
    Miyatake, T.
    Tanaka, N.
    GYNECOLOGICAL ENDOCRINOLOGY, 2018, 34 (04) : I - I
  • [2] Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer
    Freelander, Allegra
    Brown, Lauren J.
    Parker, Andrew
    Segara, Davendra
    Portman, Neil
    Lau, Brandon
    Lim, Elgene
    GENES, 2021, 12 (02) : 1 - 24
  • [3] Disparities in Hormone Receptor-Positive Breast Cancer
    Ogayo, Esther R.
    Mittendorf, Elizabeth A.
    Kantor, Olga
    CURRENT BREAST CANCER REPORTS, 2024, 16 (01) : 106 - 115
  • [4] Palbociclib for hormone receptor-positive breast cancer
    Harding, Emilia
    LANCET ONCOLOGY, 2015, 16 (07): : E318 - E318
  • [5] Disparities in Hormone Receptor-Positive Breast Cancer
    Esther R. Ogayo
    Elizabeth A. Mittendorf
    Olga Kantor
    Current Breast Cancer Reports, 2024, 16 : 106 - 115
  • [6] A PhaseIITrial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone Metastases
    Xu, Jing
    Higgins, Michaela J.
    Tolaney, Sara M.
    Come, Steven E.
    Smith, Matthew R.
    Fornier, Monica
    Mahmood, Umar
    Baselga, Jose
    Yeap, Beow Y.
    Chabner, Bruce A.
    Isakoff, Steven J.
    ONCOLOGIST, 2020, 25 (08): : 652 - 660
  • [7] Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer
    Almstedt, Katrin
    Schmidt, Marcus
    BREAST CARE, 2015, 10 (03) : 168 - 172
  • [8] Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer
    Sehdev, S.
    Martin, G.
    Sideris, L.
    Lam, W.
    Brisson, S.
    CURRENT ONCOLOGY, 2009, 16 : S16 - S25
  • [9] Androgen Receptor in Hormone Receptor-Positive Breast Cancer
    Khan, Ashfia Fatima
    Karami, Samaneh
    Peidl, Anthony S.
    Waiters, Kacie D.
    Babajide, Mariam Funmi
    Bawa-Khalfe, Tasneem
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (01)
  • [10] The Natural History of Hormone Receptor-Positive Breast Cancer
    Lim, Elgene
    Metzger-Filho, Otto
    Winer, Eric P.
    ONCOLOGY-NEW YORK, 2012, 26 (08): : 688 - +
12345